Expression of scFv SA3 against hepatoma fused with enhanced green fluorecsent protein and its targeted ability in vivo

Journal of Central South University (Medical Sciences)

Volumn 36, Issue 10, 2011, Pages 979-986

  Huang, Jian ^a,b,c   Li, Yuehui ^a,b,c   Guo, Fengjie ^a,b,c   Tong, Yongqing ^a,b,c   Wang, Jiajia ^a,b,c   Hu, Jinyue ^a,b,c   Li, Guancheng ^a,b,c  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b BEIJING HOSPITAL   (China)

^c BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

EGFP; Fusion expression; Hepatoma; Prokaryotic expression; ScFv; Targeted therapy

Indexed keywords

CANCER ANTIBODY; GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; SCFV GREEN FLUORESCENT PROTEIN, RECOMBINANT; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANIMAL; ARTICLE; BIOSYNTHESIS; CANCER TRANSPLANTATION; CELL STRAIN HEPG2; ESCHERICHIA COLI; FEMALE; GENE VECTOR; GENETICS; HUMAN; IMMUNOLOGY; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUSE; NUDE MOUSE;

ANIMALS; ANTIBODIES, NEOPLASM; CARCINOMA, HEPATOCELLULAR; ESCHERICHIA COLI; FEMALE; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; NEOPLASM TRANSPLANTATION; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES;

EID: 82555193673     PISSN: 16727347     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1672-7347.2011.10.008     Document Type: Article

References (26)

1. Hussain S P, Schwank J, Staib F, et al. TP53 mutations and hepatocellular carcinoma; insights into the etiology and pathogenesis of liver cancer[J]. Oncogene, 2007,26 (15): 2166-2176. (Pubitemid 46536641)
2. Parkin D M, Bray F, Ferlay J, et al. Global cancer statistics, 2002 [J]. CA Cancer J Clin, 2005, 55(2): 74-108. (Pubitemid 40372904)
3. Pisani P, Parkin D M, Bray F, et al. Erratum: Estimates of the worldwide mortality from 25 cancers in 1990[J]. Int J Cancer, 1999, 83(6): 870-873.
4. Lu Y M, Qin H, Wang C B, et al. Comparison of therapeutic effectiveness of combined interventional therapy for 1126 cases of primary liver cancer [J]. World J Gastroenterol, 2006,12 (31) : 5060-5063. (Pubitemid 44323280)
5. Wu A M, Senter P D. Arming antibodies : prospects and challenges for immunoconjugates [J]. Nat Biotechnol, 2005, 23 (9) : 1137-1146. (Pubitemid 41486395)
6. Balhom R, Hok S, Burke P A, et al. Selective high-affinity ligand antibody mimics for cancer diagnosis and therapy:initial application to lymphoma/leukemia [ J ]. Clin Cancer Res, 2007, 13(18 Pt 2): 5621s-5628s. (Pubitemid 47510396)
7. Fietz T, Thiel E. Antibody therapy in non-Hodgkin's lymphoma:the role of rituximab, 90Y-ibritumomab tiuxetan, and alemtuzumab[J]. Recent Results Cancer Res, 2007, 176:153-163.
8. Berger M, Shankar V, Vafai A. Therapeutic applications of monoclonal antibodies[ J]. Am J Med Sci,2002,324 (1) : 14-30. (Pubitemid 34759961)
9. Onda M, Wang Q C, Guo H F, et al. In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma and neuroblastoma [J]. Cancer Res, 2004, 64(4) : 1419-1424. (Pubitemid 38235611)
10. Decker T, Oelsner M, Kreitman R J, et al. Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins [J]. Blood 2004, 103(7): 2718-2726. (Pubitemid 38393030)
11. Leath C A 3rd, Douglas J T, Curiel D T, et al. Single-chain antibodies : A therapeutic modality for cancer gene therapy (review) [J]. Int J Oncol,2004, 24(4): 765-771.
12. Wu J, Nantz M H, Zem M A. Targeting hepatocytes for drug and gene delivery: emerging novel approaches and applications [J]. Front Biosci, 2002, 7(3): d717-725.
13. McCafferty J, Griffiths A D, Winter G, et al. Phage antibodies: filamentous phage displaying antibody variable domains [J]. Nature, 1990,348 (6301): 552-554. (Pubitemid 120015109)
14. Figini M, Marks J D, Winter G, et al. In vitro assembly of repertoires of antibody chains on the surface of phage by renaturation[J]. J Mol Biol,1994,239(1) : 68-78. (Pubitemid 24175082)
15. Marty C, Langer-Machova Z, Sigrist S, et al. Isolation and characterization of a scFv antibody specific for tumor endothelial marker 1 (TEM I), a new reagent for targeted tumor therapy [J]. Cancer Lett, 2006, 235(2): 298-308.
16. 0[J]. Proc Natl Acad Sci USA, 2006,103(2): 407412.
17. Letchford J, Cardwell A M, Stewart K, et al. Isolation of C15: a novel antibody generated by phage display against mesenchymal stem cell-enriched fractions of adult human marrow[ J]. J Immunol Methods,2006,308 (1/2): 124-137. (Pubitemid 43107961)
18. HUANG Jian, XIAO Yan, TONG Yongqing, et al. Selection and characterization of human scFv antibodies against hepatocellular carcinoma[ J]. Chinese Journal of Cellular and Molecular Immunology,2008,24(3) : 256-259.
19. Zitzmann S, Mier W, Schad A, et al. A new prostate carcinoma binding peptide (DUP-I) for tumor imaging and therapy [J]. Clin Cancer Res, 2005,11 (1) : 139-146. (Pubitemid 40075788)
20. Zhang Q, Bai G, Cheng J, et al. Use of an enhanced green fluorescence protein linked to a single chain fragment variable antibody to localize Bursaphelenchus xylophilus cellulase [J]. Biosci Biotechnol Biochem, 2007, 71(6): 1514-1520. (Pubitemid 47012019)
21. Heim R, Cubitt A B, Tsien R Y. Improved green fluorescence [J]. Nature,1995, 373 (6516) : 663-664.
22. Casey W M, Nguyen N A. Use of the green fluorescent protein to rapidly assess viability of E. coli in preserved solutions[J]. PDA J Pharm Sci Techno[J], 1996, 50 (6) : 352-355.
23. Leff L G, Leff A A. Use of green fluorescent protein to monitor survival of genetically engineered bacteria in aquatic environments[J]. Appl Environ Microbiol, 1996,62(9): 3486-3488. (Pubitemid 26304149)
24. Ward W W, Bokman S H. Reversible denaturation of Aequorea green fluore- scent protein: physical separation and characterization of the renatured protein [J]. Biochemistry, 1982, 21 (19): 4535-4540.
25. Stauber R H, Horie K, Carney P, et al. Development and applications of enhanced green fluorescent protein mutants [J]. Biotechniques, 1998, 24(3): 462466, 468471.
26. Yokota T, Milenic D E, Whitlow M, et al. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms[ J]. Cancer Res, 1992,52 (12): 3402-3408.